Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Volenrelaxin in Healthy Participants
NCT04768855Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of volenrelaxin in heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Day 113. Started Mar 2021; status: completed.
02
Drugs
volenrelaxin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04768855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768855.